<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To assess the effect of Loeys-Dietz syndrome (LDS) mutations affecting TGFΒR1 a selection of seven disease-associated amino acid substitutions were introduced into <z:mp ids='MP_0002169'>wild type</z:mp> TGFβR1 and constitutively active TGFβR1(T204D) </plain></SENT>
<SENT sid="1" pm="."><plain>Receptor function was tested by co-transfection with a luciferase reporter or EGFP-tagged SMAD2 in HEK293 cells </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the mutations were found to be inactivating for canonical TGF-β signaling </plain></SENT>
<SENT sid="3" pm="."><plain>Differences in residual activity were not found to correlate with disease subtype </plain></SENT>
<SENT sid="4" pm="."><plain>In co-transfection experiments with equal amounts <z:mp ids='MP_0002169'>wild-type</z:mp> receptor, the LDS mutations were found to confer a modest dominant negative effect </plain></SENT>
<SENT sid="5" pm="."><plain>These results are discussed in relation to LDS and the related <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
</text></document>